Tecentriq is a monoclonal antibody that blocks the PD-L1 protein, helping the immune system to detect and attack cancer cells. It is used in the treatment of various cancers including non-small cell lung cancer and urothelial carcinoma.
congrats on reading the definition of Tecentriq. now let's actually learn it.
Tecentriq targets the PD-L1 protein to enhance immune response against cancer cells.
It is administered via intravenous infusion.
Common side effects include fatigue, nausea, and decreased appetite.
Tecentriq was first approved by the FDA in 2016 for bladder cancer treatment.
It can be used as monotherapy or in combination with other treatments.
Review Questions
What protein does Tecentriq target to help the immune system fight cancer?
List two common side effects of Tecentriq.
In what year was Tecentriq first approved by the FDA?
Related terms
PD-L1: A protein that helps keep immune cells from attacking non-harmful cells in the body.
Monoclonal Antibody: An antibody made by identical immune cells that are all clones of a unique parent cell.
Immune Checkpoint Inhibitor: A type of drug that blocks checkpoint proteins from binding with their partner proteins, allowing T cells to kill cancer cells.